Metraipolis › archive › dc_e29b68807e7e

Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study — Europe PMC PMID:42136633

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42136633
DOI
10.3389/fimmu.2026.1750735
License (as archived)
solo-consultazione
Archived
2026-11-02T23:06:36.496Z
SHA-256 of the archived text
774cd1b608d565909f2721b1e3a63070094f2ef92a4f9627dcc4736cbb182803
Stable URL of this page
https://metraipolis.com/documento/dc_e29b68807e7e

How to cite

Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study — Europe PMC PMID:42136633 — Europe PMC (en), https://europepmc.org/article/MED/42136633 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e29b68807e7e (Metraipolis archive dc_e29b68807e7e, sha256 774cd1b608d565909f2721b1e3a63070094f2ef92a4f9627dcc4736cbb182803)
BibTeX
@misc{dce29b68807e7e,
  title = {Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study — Europe PMC PMID:42136633},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42136633},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e29b68807e7e; sha256 774cd1b608d565909f2721b1e3a63070094f2ef92a4f9627dcc4736cbb182803},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42136633. Agents can read the archived copy with the MCP tool read_document.